AstraZeneca’s next major drug approval success will occur after Q1 2027
Resolves: AstraZeneca receives FDA, EMA, or equivalent regulatory approval for a new drug (excluding line extensions or minor label updates) on or after 2027-04-01, confirmed by official regulatory body announcements.
AstraZeneca’s next major drug approval success will occur after Q1 20…
Market overview
Following the Wainua trial failure, AstraZeneca will delay or fail to secure regulatory approval for a major pipeline candidate in 2026, pushing the next significant approval event to no earlier than April 1, 2027. This will further undermine investor confidence in its pipeline execution.
regulatory prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2027-04-01
About this prediction
Resolution criteria
AstraZeneca receives FDA, EMA, or equivalent regulatory approval for a new drug (excluding line extensions or minor label updates) on or after 2027-04-01, confirmed by official regulatory body announcements.
Source: user-generated
More regulatory markets
- More than half of new river bathing sites will be rated 'poor' by 2027 — 70% Yes
- New York budget passes by May 31 with surcharge on second homes — 70% Yes
- Trump signs executive order on drug prices by June 2026 — 68% Yes
- FIFA sanctions Argentina FA by November 2026 — 70% Yes
- USAID funding for global health programs restored by 2027-03-31 — 55% Yes
- CISA will finalize updated incident playbook by 2026 year-end — 85% Yes
- OpenAI introduces age verification system for under-13 users by 2026 Q4 — 85% Yes
- UK government concedes to inflation-linked teacher pay raise by Q2 2027 — 60% Yes